Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/52645
Full metadata record
DC FieldValueLanguage
dc.contributor.authorY. Wangen_US
dc.contributor.authorS. Thongsawaten_US
dc.contributor.authorE. J. Ganeen_US
dc.contributor.authorY. F. Liawen_US
dc.contributor.authorJ. Jiaen_US
dc.contributor.authorJ. Houen_US
dc.contributor.authorH. L Y Chanen_US
dc.contributor.authorG. Papatheodoridisen_US
dc.contributor.authorM. Wanen_US
dc.contributor.authorJ. Niuen_US
dc.contributor.authorW. Baoen_US
dc.contributor.authorA. Trylesinskien_US
dc.contributor.authorN. V. Naoumoven_US
dc.date.accessioned2018-09-04T09:28:51Z-
dc.date.available2018-09-04T09:28:51Z-
dc.date.issued2013-04-01en_US
dc.identifier.issn13652893en_US
dc.identifier.issn13520504en_US
dc.identifier.other2-s2.0-84875229260en_US
dc.identifier.other10.1111/jvh.12025en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875229260&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/52645-
dc.description.abstractIn the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%) of telbivudine-treated patients, who were serum HBV DNA positive or negative and without genotypic resistance to telbivudine at the end of the GLOBE/015 trials, were enrolled into a further 2-year extension study. A group of 502 patients completed 4 years of continuous telbivudine treatment and were included in the telbivudine per-protocol population. Amongst 293 HBeAg-positive patients, 76.2% had undetectable serum HBV DNA and 86.0% had normal serum ALT at the end of 4 years. Notably, the cumulative rate of HBeAg seroconversion was 53.2%. Amongst 209 HBeAg-negative patients, 86.4% had undetectable HBV DNA and 89.6% had normal serum ALT. In patients who had discontinued telbivudine treatment due to HBeAg seroconversion, the HBeAg response was durable in 82% of patients (median 111 weeks of off-treatment follow-up). The cumulative 4-year resistance rate was 10.6% for HBeAg-positive and 10.0% for HBeAg-negative patients. Most adverse events were mild or moderate in severity and transient. Renal function measured by estimated glomerular filtration rate (eGFR) increased by 14.9 mL/min/1.73 m2 (16.6%) from baseline to 4 years (P < 0.0001). In conclusion, in HBeAg-positive and HBeAg-negative CHB patients without resistance after 2 years, two additional years of telbivudine treatment continued to provide effective viral suppression with a favourable safety profile. Moreover, telbivudine achieved 53% of HBeAg seroconversion in HBeAg-positive patients. © 2012 Blackwell Publishing Ltd.en_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleEfficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis Ben_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Viral Hepatitisen_US
article.volume20en_US
article.stream.affiliationsThird Military Medical Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsAuckland City Hospitalen_US
article.stream.affiliationsChang Gung Memorial Hospitalen_US
article.stream.affiliationsCapital Medical University Chinaen_US
article.stream.affiliationsNanfang Hospitalen_US
article.stream.affiliationsChinese University of Hong Kongen_US
article.stream.affiliationsHippokration General Hospitalen_US
article.stream.affiliationsChanghai Hospitalen_US
article.stream.affiliationsJilin Universityen_US
article.stream.affiliationsNovartis Pharmaceuticals Corporationen_US
article.stream.affiliationsNovartis International AGen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.